- Home
- YB vs FLGT Comparison
YB vs FLGT Comparison
Compare YB & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YB
- FLGT
- Stock Information
- Founded
- YB 2019
- FLGT 2011
- Country
- YB China
- FLGT United States
- Employees
- YB N/A
- FLGT N/A
- Industry
- YB
- FLGT Medical Specialities
- Sector
- YB
- FLGT Health Care
- Exchange
- YB NYSE
- FLGT Nasdaq
- Market Cap
- YB 696.5M
- FLGT 587.3M
- IPO Year
- YB 2025
- FLGT 2016
- Fundamental
- Price
- YB $27.30
- FLGT $18.07
- Analyst Decision
- YB
- FLGT Buy
- Analyst Count
- YB 0
- FLGT 2
- Target Price
- YB N/A
- FLGT $24.00
- AVG Volume (30 Days)
- YB 169.9K
- FLGT 210.6K
- Earning Date
- YB 09-05-2025
- FLGT 08-01-2025
- Dividend Yield
- YB N/A
- FLGT N/A
- EPS Growth
- YB N/A
- FLGT N/A
- EPS
- YB 3.12
- FLGT N/A
- Revenue
- YB $493,356,990.00
- FLGT $292,448,000.00
- Revenue This Year
- YB N/A
- FLGT $11.79
- Revenue Next Year
- YB N/A
- FLGT $10.45
- P/E Ratio
- YB $9.66
- FLGT N/A
- Revenue Growth
- YB 59.97
- FLGT 1.71
- 52 Week Low
- YB $14.04
- FLGT $14.57
- 52 Week High
- YB $31.00
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- YB N/A
- FLGT 29.01
- Support Level
- YB N/A
- FLGT $19.18
- Resistance Level
- YB N/A
- FLGT $19.96
- Average True Range (ATR)
- YB 0.00
- FLGT 0.56
- MACD
- YB 0.00
- FLGT -0.15
- Stochastic Oscillator
- YB 0.00
- FLGT 0.86
About YB YUANBAO INC. SPON ADS EACH REP 6 CL A ORD
Yuanbao Inc is a technology-driven online insurance distributor in China.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.